Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR PRESERVATIVE FREE vs MYAMBUTOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
FDA-approved: Treatment of ocular inflammation and pain following cataract surgery and corneal refractive surgery.,Off-label: Relief of seasonal allergic conjunctivitis symptoms, management of cystoid macular edema, and treatment of postoperative inflammation in other ocular procedures.
Treatment of pulmonary tuberculosis in combination with other antituberculosis agents,Treatment of extrapulmonary tuberculosis
1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
Terminal elimination half-life is approximately 5-6 hours in adults, but can be prolonged in elderly patients (up to 8-9 hours) and in patients with renal impairment (up to 13-19 hours).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
Ketorolac undergoes hepatic metabolism via hydroxylation and conjugation (glucuronidation) to inactive metabolites. It is primarily metabolized by CYP2D6 and CYP3A4 isoenzymes, with renal excretion of metabolites and unchanged drug.
Partially metabolized in the liver via dealkylation to an aldehyde intermediate, which is further oxidized to a dicarboxylic acid. Approximately 50% of the drug is excreted unchanged in urine.
Primarily renal excretion of metabolites and unchanged drug; approximately 80% of a dose is excreted in urine as ketorolac and its hydroxy metabolites, with about 6% excreted in feces.
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
99% bound to plasma proteins, primarily albumin.
20-30% bound to albumin.
0.15-0.25 L/kg after oral administration; for ophthalmic use, systemic absorption is minimal, so Vd is not clinically meaningful.
1.6 L/kg; distributes widely into tissues, including erythrocytes and cerebrospinal fluid (with inflamed meninges).
Ophthalmic administration: Systemic bioavailability is approximately 0.5-1% after ocular instillation due to low corneal penetration and rapid clearance; oral bioavailability is 100%.
Oral: approximately 80% absorbed.
No dosage adjustment required for renal impairment. Drug is minimally absorbed systemically.
Cr Cl 30-60 m L/min: 15-20 mg/kg daily; Cr Cl 10-29 m L/min: 15 mg/kg every 24-36 hours; Cr Cl <10 m L/min: 15 mg/kg every 48 hours.
No dosage adjustment required for hepatic impairment. Drug is minimally absorbed systemically.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
Children ≥3 years: 1 drop into affected eye(s) four times daily. Safety and efficacy in children <3 years not established.
15-25 mg/kg orally once daily (max 1 g/day for children weighing <20 kg, otherwise 2.5 g/day).
No specific dosage adjustment required. Use same dose as adults; monitor for tolerability.
Consider reduced initial dose based on renal function; monitor for optic neuritis.
NSAIDs may increase the risk of serious cardiovascular events (e.g., myocardial infarction, stroke) and gastrointestinal events (e.g., bleeding, ulceration, perforation). However, due to low systemic absorption with ophthalmic use, this boxed warning is less clinically relevant but still applies.
MYAMBUTOL may cause optic neuritis and decreased visual acuity, which may be dose-related and reversible upon discontinuation. Not recommended for use in children under 13 years of age.
Use with caution in patients with compromised ocular surface, history of herpes simplex keratitis, bleeding tendencies, or those on anticoagulants. Prolonged use may delay wound healing. Monitor for signs of corneal epithelial breakdown or infection.
Optic neuritis (monitor visual acuity and color discrimination); hepatic toxicity; renal impairment (dose adjustment required); interaction with aluminum-containing antacids (decreased absorption).
Hypersensitivity to ketorolac or any component of the formulation; patients with active ocular infection or advanced dry eye; history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs.
Hypersensitivity to ethambutol; optic neuritis (unless benefit outweighs risk); children under 13 years of age (relative contraindication).
No known food interactions. No dietary restrictions required.
No significant food interactions. However, administration with food may reduce gastrointestinal upset. Concurrent use with aluminum-containing antacids may decrease absorption; separate by at least 2 hours.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to 1.5-3 times the human exposure. However, because NSAIDs can cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester, use is contraindicated after 30 weeks gestation. In first and second trimesters, use only if potential benefit justifies potential fetal risk.
Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant increase in major malformations. However, due to the risk of optic neuritis in the mother, use during pregnancy should be cautious and only if clearly needed.
Ketorolac is excreted in human milk following oral administration. After a single intramuscular dose of 10 mg, the milk-to-plasma (M/P) ratio was 0.037. Low levels are expected in breastmilk; however, due to potential adverse effects of NSAIDs on neonates, caution is advised. Use is generally avoided in nursing mothers, especially with premature infants or those with thrombocytopenia or renal impairment.
Ethambutol is excreted into human breast milk in low concentrations; the estimated infant dose is approximately 2-4% of the maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.57. The American Academy of Pediatrics considers ethambutol compatible with breastfeeding. Monitor the infant for signs of optic neuritis or gastrointestinal effects.
No specific pharmacokinetic studies in pregnancy. Dosing should be at the lowest effective dose for the shortest duration. Avoid use after 30 weeks gestation. No adjustment for first or second trimester unless renal function changes.
No specific dose adjustments are routinely recommended during pregnancy. However, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may reduce serum concentrations; therapeutic drug monitoring is not standard but may be considered. Adjust dose based on renal function; usual dose is 15-25 mg/kg/day, not to exceed 2.5 g/day.
ACULAR (ketorolac tromethamine ophthalmic solution) is an NSAID for ocular use. Preservative-free formulation is indicated for single-use to avoid corneal toxicity. Apply with caution in patients with bleeding disorders or those on anticoagulants due to risk of ocular bleeding. Prolonged use may delay corneal healing. Monitor for signs of keratitis or conjunctival hyperemia.
MYAMBUTOL (ethambutol) is a bacteriostatic agent used primarily in combination therapy for tuberculosis. Monitor for optic neuritis, which can cause decreased visual acuity, color blindness, and visual field defects; baseline and monthly visual acuity and color discrimination tests are mandatory. Dose adjustments required in renal impairment (Cr Cl <30 m L/min). Avoid in children <13 years old due to inability to monitor vision. May cause hyperuricemia; monitor uric acid levels in patients with gout.
Use exactly as prescribed; do not touch the dropper tip to any surface to avoid contamination.,Each single-use vial is for one dose only; discard after use to prevent infection.,Remove contact lenses before instillation and wait 10 minutes before reinserting.,Do not drive or operate machinery if vision is blurry after application.,Report eye pain, increased redness, or vision changes to your doctor immediately.
Take exactly as prescribed, usually once daily, with or without food.,Report any changes in vision immediately, such as blurred vision, difficulty seeing colors, or blind spots.,Avoid consuming alcohol; may increase risk of liver toxicity.,Do not stop taking this medication even if you feel better; complete full course to prevent resistance.,This drug may cause numbness or tingling in hands or feet; report these symptoms.,Inform your doctor if you have kidney disease, gout, or eye problems before starting treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR PRESERVATIVE FREE vs MYAMBUTOL, answered by our medical review team.
ACULAR PRESERVATIVE FREE is a NSAID Ophthalmic that works by Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.. MYAMBUTOL is a Antitubercular Agent that works by Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR PRESERVATIVE FREE and MYAMBUTOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR PRESERVATIVE FREE is: 1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.. The standard adult dose of MYAMBUTOL is: 15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR PRESERVATIVE FREE and MYAMBUTOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR PRESERVATIVE FREE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to. MYAMBUTOL is classified as Category C. Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.